References
- National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16–18, 2000. Pediatrics 2001;108:972-82
- Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417-27
- Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014;16:188-200
- Sapropterin dihydrochloride [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc.; 2015
- Pegvaliase-pqpz [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc.; 2018
- Thomas J, Levy H, Amato S, et al. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab 2018;124:27-38
- Longo N, Harding CO, Burton BK, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet 2014;384:37-44
- Blau N, Longo N. Alternative therapies to address the unmet medical needs of patients with phenylketonuria. Expert Opin Pharmacother 2015;16:791-800
- Harding CO, Amato RS, Stuy M, et al. Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Mol Genet Metab 2018;124:20-6
- Medroxyprogesterone acetate [prescribing information]. New York, NY: Pfizer Inc.; 2017
- Brown CS, Lichter-Konecki U. Phenylketonuria (PKU): a problem solved? Mol Genet Metab Rep 2015;6:8-12
- BioMarin Pharmaceutical Inc. European Medicines Agency (EMA) accepts BioMarin’s marketing application for pegvaliase MAA for treatment of phenylketonuria (PKU) [Internet]. San Rafael: PRNewswire; 2018. Available at: http://investors.biomarin.com/2018-03-28-European-Medicines-Agency-EMA-Accepts-BioMarins-Marketing-Application-for-Pegvaliase-MAA-for-Treatment-of-Phenylketonuria-PKU [Last accessed June 15, 2018]